首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1624442

免疫療法藥物市場規模（按治療領域、最終用戶、藥物類型、地區、範圍和預測）

Immunotherapy Drugs Market Size by Therapy Area, By End-User, By Type of Drugs, By Geographic Scope and Forecast

出版日期: 2024年09月29日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

免疫治療市場估值，2024 年至 2031 年

免疫治療藥物的需求日益增長，為多種癌症、自體免疫疾病和傳染病患者帶來了新的希望。與傳統療法不同，免疫療法利用人體免疫系統來識別和對抗疾病，使其能夠針對特定細胞，副作用可能更少。隨著全球癌症發病率持續上升，對能夠提供持久反應的有效治療方法的需求正在推動該領域的研究和應用。預計2024年市場規模將超過2,567.8億美元，2031年將達到約5,687.1億美元。

檢查點抑制劑、CAR-T 細胞療法和單株抗體等免疫療法藥物在臨床試驗中已取得巨大成功，進一步促進了它們納入標準治療方案和需求。對具有成本效益的免疫療法藥物的需求不斷增長，推動市場在 2024 年至 2031 年期間的複合年增長率達到 10.45%。

免疫療法市場定義/概述

免疫治療藥物是一類旨在增強或改變人體免疫反應以識別和攻擊致病細胞的治療方法。與直接針對疾病的傳統治療方法不同，免疫療法利用免疫系統瞄準和摧毀異常細胞，通常專注於區分異常細胞和健康細胞的特定標記。這些藥物代表了一系列的方法，包括檢查點抑制劑、CAR-T 細胞療法、單株抗體和細胞因子，每種藥物都旨在增強免疫反應或降低對疾病細胞的免疫耐受性。免疫療法在治療癌症、慢性感染和某些自體免疫疾病方面特別有效，因為它比傳統療法產生更有針對性的反應，副作用也更少。

隨著研究不斷擴大免疫療法藥物的應用範圍，其未來前景十分光明。基因組學和分子生物學的技術進步正在推動下一代免疫療法的發展，包括基於個體基因特徵的個人化治療。

此外，免疫療法可望超越原先的癌症治療，用於治療自體免疫疾病和傳染病。隨著我們對免疫途徑的理解不斷提高，製藥業正在大力投資免疫療法研發，再加上支持性監管政策，可能會擴大免疫療法的影響和可用性。這些軌跡表明免疫療法將在未來醫學中發揮關鍵作用，為複雜疾病提供更有針對性和持久的解決方案。

全球癌症發生率的不斷上升將如何推動免疫療法市場？

全球癌症發生率上升是免疫治療藥物市場發展的主要驅動力。根據世界衛生組織估計，2020年癌症死亡人數將達到近1,000萬人，預計到2040年新病例數將增加60%，對有效治療的需求日益增加。根據美國癌症協會報告，免疫療法藥物，尤其是檢查點抑制劑，在治療黑色素瘤等癌症方面已顯示出良好的效果，其反應率高達40%，改善了患者的治療效果。越多的人採用這些療法來治療

自體免疫疾病的增加是免疫治療藥物市場的主要動力。根據美國國立衛生研究院統計，美國有超過2,400萬人患有自體免疫疾病；而根據美國自體免疫相關疾病協會（AARDA）統計，發生率每年增加19%。由於女性患上這些疾病的可能性是男性的兩倍，因此對免疫療法藥物等有效治療方法的需求迅速增長。這一趨勢凸顯了對管理和治療自體免疫疾病的創新療法的需求，從而推動了市場的成長。

治療費用的上漲將如何阻礙免疫療法市場的成長？

治療費用高是阻礙免疫治療藥物市場成長的主要因素。由於複雜的研究、開發和製造過程，免疫療法治療往往費用昂貴，許多患者無法接受治療，尤其是那些沒有足夠保險覆蓋的患者。這些經濟障礙限制了患者接受治療的機會，儘管免疫療法有可能用於治療一系列疾病，但經濟問題阻礙了其廣泛採用，導致市場佔有率有限。

某些患者族群的療效有限可能會阻礙免疫療法市場的成長。免疫療法並不是萬能的，有些患者可能會因為遺傳、環境和生物因素而反應不佳，限制了其整體影響和採用。治療結果的這種差異將削弱醫療服務提供者和患者的信心，減緩免疫療法藥物的接受度和廣泛使用，最終影響市場成長。

The demand for immunotherapy drugs is rising as these treatments offer new hope for patients with various forms of cancer, autoimmune diseases, and infectious conditions. Unlike traditional therapies, immunotherapy works by harnessing the body's immune system to recognize and fight diseases, making it a powerful alternative that can target specific cells with potentially fewer side effects. As cancer rates continue to climb globally, the need for effective treatments with durable responses has driven research and adoption in this field. The market size surpass USD 256.78 Billion valued in 2024 to reach a valuation of around USD 568.71 Billion by 2031.

Immunotherapy drugs such as checkpoint inhibitors, CAR T-cell therapies, and monoclonal antibodies have shown significant success in clinical trials, further propelling their demand and integration into standard treatment protocols. The rising demand for cost-effective and immunotherapy drugs is enabling the market grow at aCAGR of 10.45% from 2024 to 2031.

Immunotherapy Drugs Market: Definition/ Overview

Immunotherapy drugs are a class of treatments designed to enhance or modify the body's immune response to recognize and attack disease-causing cells. Unlike traditional treatments, which directly target the disease, immunotherapy leverages the immune system to target and destroy abnormal cells, often with a focus on specific markers that distinguish them from healthy cells. These drugs encompass a variety of approaches, including checkpoint inhibitors, CAR T-cell therapies, monoclonal antibodies, and cytokines, each designed to either boost immune responses or reduce immune tolerance to disease cells. Immunotherapy has proven especially effective in treating cancers, chronic infections, and certain autoimmune diseases by creating a more targeted response, with the potential for fewer side effects compared to conventional therapies.

The future scope of immunotherapy drugs is highly promising as research continues to expand its applications across more diseases. Technological advancements in genomics and molecular biology are driving the development of next-generation immunotherapies, including personalized treatments based on an individual's genetic profile.

The use of immunotherapy is also expected to increase in treating autoimmune conditions and infectious diseases, moving beyond its initial focus on oncology. As the understanding of immune pathways grows, the pharmaceutical industry is investing heavily in immunotherapy R&D, which, combined with supportive regulatory policies, is likely to broaden its impact and availability. This trajectory suggests immunotherapy will play a pivotal role in the future of medicine, providing more targeted and durable solutions for complex diseases.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Will the Rising Cancer Incidence Worldwide Drive the Immunotherapy Drugs Market?

The rising global incidence of cancer is a significant driver for the immunotherapy drugs market. With cancer responsible for nearly 10 million deaths in 2020 and new cases projected to increase by 60% by 2040, according to the WHO, there is a growing demand for effective treatments. Immunotherapy drugs, especially checkpoint inhibitors, have demonstrated promising results with up to 40% response rates in cancers like melanoma, as reported by the American Cancer Society, leading to increased adoption of these therapies to improve patient outcomes.

The growing prevalence of autoimmune diseases is a major driver of the Immunotherapy Drugs Market. According to the NIH, over 24 million people in the United States are affected by autoimmune disorders, and the American Autoimmune Related Diseases Association (AARDA) notes an annual increase of 19% in cases. With women twice as likely to develop these conditions, the demand for effective treatments, such as immunotherapy drugs, is rising rapidly. This trend underscores the need for innovative therapies to manage and treat autoimmune diseases, thus fueling market growth.

How Does the High Cost of Treatment Hamper the Growth of the Immunotherapy Drugs Market?

The high cost of treatment is a significant factor hampering the growth of the Immunotherapy Drugs Market. Immunotherapy treatments are often expensive due to the complex research, development, and production processes involved, making them less accessible to many patients, especially those without adequate insurance coverage. This financial barrier limits patient access to these therapies, restricting market growth as affordability issues deter widespread adoption despite the potential benefits of immunotherapy in treating various diseases.

Limited efficacy in certain patient populations can hamper the growth of the Immunotherapy Drugs Market. Immunotherapy is not universally effective, as some patients may not respond well due to genetic, environmental, or biological factors, which restricts its overall impact and adoption. This variability in treatment outcomes reduces confidence among healthcare providers and patients, slowing down the acceptance and widespread use of immunotherapy drugs and ultimately affecting market growth.

Category-Wise Acumens

Will the Proven Efficacy Propel the Checkpoint Inhibitors Segment for the Immunotherapy Drugs Market?

The checkpoint inhibitors segment is dominating the immunotherapy drugs market. The proven efficacy of checkpoint inhibitors is propelling the checkpoint inhibitors segment in the immunotherapy drugs market. These drugs have shown remarkable success in treating various cancers, especially by enhancing the body's immune response to target and destroy cancer cells more effectively. Their ability to improve survival rates in challenging cases, such as advanced melanoma and lung cancer, has driven strong demand from healthcare providers and patients alike. With ongoing research expanding their use across different cancer types, the efficacy of checkpoint inhibitors continues to strengthen their role in cancer therapy.

The favorable safety profile is propelling the checkpoint inhibitors segment in the Immunotherapy Drugs Market. Checkpoint inhibitors target specific pathways in cancer cells, allowing the immune system to attack cancer more effectively with fewer side effects compared to traditional therapies like chemotherapy. This targeted approach reduces the risk of widespread toxicity, making these drugs safer and better tolerated by patients. As a result, the preference for checkpoint inhibitors is growing, particularly for long-term cancer treatment, driving their demand in the immunotherapy drugs market.

Will the High Prevalence of Diseases Promote the Healthcare Institutions Segment for the Immunotherapy Drugs Market?

The healthcare institutions segment is ruling the immunotherapy drugs market. The high prevalence of diseases, particularly cancer and autoimmune disorders, is promoting the healthcare institutions segment in the immunotherapy drugs market. As the incidence of these diseases rises globally, healthcare institutions are increasingly adopting advanced immunotherapy treatments to improve patient outcomes. Immunotherapy drugs, such as checkpoint inhibitors and monoclonal antibodies, offer promising alternatives to traditional treatments, attracting healthcare providers seeking more effective therapies. The growing demand for innovative treatments within hospitals and clinics is driving the expansion of immunotherapy drug usage in healthcare settings.

Advanced medical infrastructure is promoting the Healthcare Institutions segment in the Immunotherapy Drugs Market. With improved healthcare facilities, technology, and expertise, institutions are better equipped to administer complex immunotherapies, including precision medicine and advanced biologics. The availability of cutting-edge diagnostic tools and treatment protocols enables healthcare providers to deliver these therapies more effectively, improving patient outcomes. As hospitals and clinics enhance their capabilities, the demand for innovative immunotherapy drugs continues to rise, driving growth in this segment.

Country/Region-wise Acumens

Will the Disease Prevalence and Patient Population Accelerate the North American Region for the Immunotherapy Drugs Market?

North America's dominance in the immunotherapy drugs market is driven by several factors. Disease prevalence and a large patient population are accelerating the Immunotherapy Drugs Market in North America. In 2023, the American Cancer Society reported around 1.9 million new cancer diagnoses, with immunotherapy as a primary treatment option, and the National Cancer Institute noted that 40% of U.S. cancer patients are eligible for these therapies. Additionally, autoimmune diseases affect approximately 23.5 million Americans and are rising by 4-7% annually. This high prevalence of cancer and autoimmune conditions creates a substantial demand for immunotherapy treatments, driving market growth in the region.

Advanced healthcare infrastructure is accelerating the Immunotherapy Drugs Market in North America. The region boasts over 1,500 cancer centers offering immunotherapy treatments, and 89% of oncologists now prescribe immunotherapy as a first-line option for eligible patients. Additionally, expanded Medicare coverage for CAR T-cell therapy, now covering 85% of eligible patients, makes these innovative treatments more accessible. This robust infrastructure and supportive coverage landscape enhance patient access and adoption of immunotherapy, driving significant market growth in North America.

Will the Healthcare Infrastructure Improvements Expand the Asia Pacific region for Immunotherapy Drugs Market?

Asia Pacific is rapidly growing in the immunotherapy drugs market. Healthcare infrastructure improvements are driving the Immunotherapy Drugs Market in the Asia Pacific region. China's "Healthy China 2030" initiative emphasizes enhanced cancer care and the development of immunotherapies, while India's National Health Policy 2017 aims for universal health coverage, including access to advanced cancer treatments. Additionally, Japan's substantial investment of JPY 1.1 trillion in healthcare R&D, focusing on innovative oncology therapies, strengthens the region's capacity to support and expand immunotherapy options. These initiatives collectively boost accessibility, research, and adoption of immunotherapies, accelerating market growth in the Asia Pacific.

A supportive regulatory environment is accelerating the Immunotherapy Drugs Market in the Asia Pacific region. In 2023, China's National Medical Products Administration (NMPA) approved 15 new immunotherapy drugs, signaling strong support for these treatments. India's Central Drugs Standard Control Organization (CDSCO) has streamlined approval processes specifically for immune-oncology therapies, while Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has introduced expedited review pathways for breakthrough immunotherapies. These regulatory advancements facilitate faster market entry and access, boosting the availability and adoption of immunotherapy drugs across the Asia Pacific.

Competitive Landscape

The immunotherapy drugs market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the immunotherapy drugs market include:

Roche
Merck & Co.
Bristol-Myers Squibb
Novartis
Pfizer
Amgen
AstraZeneca
Gilead Sciences
Johnson & Johnson
GlaxoSmithKline

Latest Developments

In September 2023, NextCure announced the initiation of a Phase I/II trial (NCT03665285) to evaluate the safety and tolerability of NC318 as a potential treatment for advanced or metastatic solid tumors. The trial includes assessments for conditions such as head and neck squamous cell carcinoma, non-small cell lung cancer, and ovarian cancer.
In January 2022, Immunocore Ltd, a biotechnology company, got FDA clearance for tebentafusp-tebn (Kimmtrak), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, for adult patients with unresectable or metastatic uveal melanoma and HL:01.

1 INTRODUCTION OF GLOBAL IMMUNOTHERAPY DRUGS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL IMMUNOTHERAPY DRUGS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA

5.1 Overview
5.2 Cancer
5.3 Autoimmune and Inflammatory Diseases
5.4 Infectious Diseases
5.5 Other Therapy Areas

6 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END-USER

6.1 Overview
6.2 Hospitals
6.3 Clinics
6.4 Others

7 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUG

7.1 Overview
7.2 Monoclonal Antibodies
7.3 Adult Vaccines
- 7.3.1 Preventive Vaccines
- 7.3.2 Therapeutic Vaccines
7.4 Checkpoint Inhibitors
7.5 Interferons Alpha & Beta
7.6 Interleukins
7.7 Other Drugs

8 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL IMMUNOTHERAPY DRUGS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Share
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 F. Hoffmann-La Roche Ltd. (UK)
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Merck & Co (US)
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Novartis International AG (UK)
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Johnson & Johnson (US)
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Sanofi (France)
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 GlaxoSmithKline Plc (UK)
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Amgen Inc. (US)
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 AbbVie Inc. (US)
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Boehringer Ingelheim (Germany)
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 AstraZeneca (UK)
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments